Regional perfusion treatment with melphalan for melanoma in a limb: an evaluation of drug kinetics
- PMID: 3360157
Regional perfusion treatment with melphalan for melanoma in a limb: an evaluation of drug kinetics
Abstract
The time course of tissue levels of melphalan during normothermic isolated limb perfusion, and the overall tissue levels per 60 min of perfusion, were estimated from the known pharmacokinetic parameters for a fixed dose of drug per liter of tissue (Benckhuijsen et al., J. Pharmacol Exp Ther 1986; 237: 583-8). The application of differing total doses of drug resulted in varying concentrations in the perfusate plasma. Above a certain plasma level, uptake into the bulk of the tissues did not increase with the area under the plasma concentration vs time curve or its beta-phase. Similar tissue levels were found after perfusion of regions of less than three and a half liter with 13 mg/l as in regions of 5 to 16 liter after perfusion with 10 mg of melphalan per liter. It cannot be predicted from the available data whether the extent of uptake of melphalan into the tumour tissue is equal to or greater than that into the bulk of the tissues. The estimated uptake of drug into the tissues confirms the validity of the dose calculation per liter of tissue. On the basis of the present results, a refined dosimetric formula will be obtainable that includes the desired area under the plasma concentration vs time curve as a determinant for an optimal dose.
Similar articles
-
Pharmacokinetics of melphalan in isolated perfusion of the limbs.J Pharmacol Exp Ther. 1986 May;237(2):583-8. J Pharmacol Exp Ther. 1986. PMID: 3701643
-
Microdialysis and response during regional chemotherapy by isolated limb infusion of melphalan for limb malignancies.Br J Cancer. 2001 Jul 20;85(2):157-65. doi: 10.1054/bjoc.2001.1902. Br J Cancer. 2001. PMID: 11461070 Free PMC article. Clinical Trial.
-
Regional toxicity after isolated limb perfusion with melphalan and tumour necrosis factor- alpha versus toxicity after melphalan alone.Eur J Surg Oncol. 2001 Jun;27(4):390-5. doi: 10.1053/ejso.2001.1124. Eur J Surg Oncol. 2001. PMID: 11417986
-
Isolated limb perfusion for melanoma.Surg Oncol Clin N Am. 2008 Oct;17(4):785-94, viii-ix. doi: 10.1016/j.soc.2008.04.005. Surg Oncol Clin N Am. 2008. PMID: 18722918 Review.
-
The use of tumour necrosis factor (TNF) in isolated perfusion: results and side effects. The NCI results.Melanoma Res. 1994 Mar;4 Suppl 1:27-9. Melanoma Res. 1994. PMID: 8038592 Review.
Cited by
-
The pharmacokinetic advantages of isolated limb perfusion with melphalan for malignant melanoma.Br J Cancer. 1992 Jul;66(1):159-66. doi: 10.1038/bjc.1992.235. Br J Cancer. 1992. PMID: 1637666 Free PMC article.
-
Hyperthermic isolated limb perfusion for malignant melanoma: response and survival.World J Surg. 1995 May-Jun;19(3):363-8. doi: 10.1007/BF00299159. World J Surg. 1995. PMID: 7638989
-
Optimization of isolated hyperthermic limb perfusion.World J Surg. 1992 Nov-Dec;16(6):1117-9. doi: 10.1007/BF02067073. World J Surg. 1992. PMID: 1455882 Clinical Trial.
-
Prerequisites for effective isolated limb perfusion using tumour necrosis factor alpha and melphalan in rats.Br J Cancer. 1999 Apr;80(1-2):161-6. doi: 10.1038/sj.bjc.6690335. Br J Cancer. 1999. PMID: 10389992 Free PMC article.
-
Isolated limb perfusion with actinomycin D and TNF-alpha results in improved tumour response in soft-tissue sarcoma-bearing rats but is accompanied by severe local toxicity.Br J Cancer. 2002 Apr 8;86(7):1174-9. doi: 10.1038/sj.bjc.6600169. Br J Cancer. 2002. PMID: 11953868 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Medical